Rep. Byron Donalds Sells Off Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock

Representative Byron Donalds (R-Florida) recently sold shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Vertex Pharmaceuticals stock on March 20th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Gartner (NYSE:IT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Equifax (NYSE:EFX) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Tradeweb Markets (NASDAQ:TW) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 3/20/2025.

Vertex Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ:VRTX traded up $3.82 during mid-day trading on Thursday, hitting $489.71. The company had a trading volume of 462,439 shares, compared to its average volume of 1,324,356. The firm has a fifty day moving average price of $485.70 and a 200 day moving average price of $464.91. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The company has a market capitalization of $125.75 billion, a PE ratio of -222.59, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. As a group, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Institutional Trading of Vertex Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Brown Lisle Cummings Inc. bought a new position in Vertex Pharmaceuticals in the 4th quarter worth $30,000. Mascagni Wealth Management Inc. purchased a new stake in shares of Vertex Pharmaceuticals during the fourth quarter valued at $31,000. Sugar Maple Asset Management LLC bought a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $35,000. Golden State Wealth Management LLC bought a new position in shares of Vertex Pharmaceuticals in the fourth quarter worth about $37,000. Finally, Truvestments Capital LLC lifted its holdings in Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company’s stock valued at $40,000 after purchasing an additional 23 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

VRTX has been the subject of several research analyst reports. Oppenheimer lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Canaccord Genuity Group raised Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Truist Financial boosted their target price on Vertex Pharmaceuticals from $460.00 to $520.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, Bank of America boosted their price objective on shares of Vertex Pharmaceuticals from $555.00 to $567.00 and gave the company a “buy” rating in a research report on Monday, March 31st. Ten analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $512.41.

Insider Buying and Selling at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the completion of the sale, the executive vice president now directly owns 26,512 shares of the company’s stock, valued at approximately $13,256,000. This trade represents a 10.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares of the company’s stock, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 4,315 shares of company stock valued at $2,121,012 over the last ninety days. 0.20% of the stock is currently owned by company insiders.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.